SAN FRANCISCO — Lawyers from Gibson, Dunn & Crutcher helped Botox-maker Allergan Inc. put together a $157 million agreement that lets the company have access to Map Pharmaceuticals Inc.’s experimental migraine treatment Levadex, which they’ll both promote to U.S. doctors.
Gibson, Dunn Palo Alto partner Gregory Davidson led the team for Irvine-based Allergan, along with attorneys in Orange County. Judith Hasko from Latham & Watkins in Menlo Park led the legal team representing Mountain View-based Map.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
